Literature DB >> 15206649

A new staging system for idiopathic retinal periphlebitis.

S Saxena1, D Kumar.   

Abstract

PURPOSE: To develop and standardize a universally acceptable new staging system for idiopathic retinal periphlebitis (Eales disease).
METHODS: A new staging system was established and standardized based on standard terminology and features. Idiopathic retinal periphlebitis was classified as peripheral and central types. Peripheral disease consisted of four stages. Stage 1 is periphlebitis of small (1a) and large (1b) caliber vessels with superficial retinal hemorrhages. Stage 2a denotes capillary nonperfusion and 2b neovascularization elsewhere/of the disc. Stage 3a is classified as fibrovascular proliferation and 3b vitreous hemorrhage. Stage 4a is traction/combined rhegmatogenous retinal detachment whereas 4b is rubeosis iridis, neovascular glaucoma, complicated cataract, and optic atrophy. A total of 253 cases of idiopathic retinal periphlebitis (mean age, 24.7 +/- 4.7 years, all male) presenting at this tertiary care center were classified prospectively according to the new staging system, by two independent observers (interobserver correlation = 0.7).
RESULTS: The new staging system was consistent, simple, and easy to recall. Peripheral and central types of idiopathic retinal periphlebitis were found in 94.07% and 5.93% of cases, respectively. The new staging system also defined the severity of the disease. Vitreous hemorrhage was found to be the commonest presenting feature (51.68%), whereas traction/combined rhegmatogenous detachment was found in 5.88% of cases.
CONCLUSIONS: The new staging system is useful in classifying and assessing the severity of disease. Management strategy can also be defined according to the stage of the disease. It is designed to promote the use of standard assessment with applications to clinical management and research.

Entities:  

Mesh:

Year:  2004        PMID: 15206649     DOI: 10.1177/112067210401400308

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  6 in total

1.  Combination of intravitreal bevacizumab and peripheral photocoagulation: an alternative treatment in eales disease.

Authors:  Juarez Cp; Gramajo Al; Luna Jd
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

2.  Tumor necrosis factor-α-mediated severity of idiopathic retinal periphlebitis in young adults (Eales' disease): implication for anti-TNF-α therapy.

Authors:  Sandeep Saxena; Aditya B Pant; Vinay K Khanna; Kamlesh Singh; Rajendra K Shukla; Carsten H Meyer; Vijay K Singh
Journal:  J Ocul Biol Dis Infor       Date:  2010-07-16

3.  Vitreopapillary and vitreomacular traction in proliferative Eales' disease.

Authors:  Sandeep Saxena; Astha Jain; Levent Akduman
Journal:  BMJ Case Rep       Date:  2012-10-29

4.  Total antioxidant capacity in Eales' disease, uveitis & cataract.

Authors:  Radhakrishnan Selvi; Narayanasamy Angayarkanni; Jyotirmay Biswas; Sivaramakrishnan Ramakrishnan
Journal:  Indian J Med Res       Date:  2011-07       Impact factor: 2.375

5.  Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease.

Authors:  Narayanasamy Angayarkanni; Radhakrishnan Selvi; Rishi Pukhraj; Jyotirmoy Biswas; Shah J Bhavesh; Joyce Tombran-Tink
Journal:  J Ocul Biol Dis Infor       Date:  2009-03-06

6.  Eales' disease - current concepts in diagnosis and management.

Authors:  Jyotirmay Biswas; Reesha Karingattil Ravi; Angayarkanni Naryanasamy; Lily Therese Kulandai; Hajib Naraharirao Madhavan
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.